TCF7L2 Polymorphisms Influence on Glycemic Control in ICU Patients With Organ Failure

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03055169

Acronym

READIAB-G4

Enrollment

994

Registered

2017-02-16

Start date

2012-04-01

Completion date

2017-08-01

Last updated

2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic Predisposition to Disease, Hyperglycemia, Intensive Care Unit Syndrome, Multiple Organ Failure

Keywords

hyperglycemia, Multiple Organ Failure, biobank, diabetes

Brief summary

This study evaluates the link between genetic polymorphisms as r7903146, rs12255372 of TCF7L2 gene and the risk of developing hyperglycemia during Intensive care unit stay

Interventions

GENETICgenetic analysis

BIOLOGICALblood and stools samples

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* admission in ICU\>48h * at least one organ dysfunction

Exclusion criteria

* age\< 18 years * pregnant women * admission less than 48h

Design outcomes

Primary

Measure	Time frame	Description
value of the odds ratio associated with the relationship between a polymorphism TCF7L2 gene and the occurrence of hyperglycemia	one year after inclusion	find a link between genetic polymorphism of TCF7L2 and the risk of developing hyperglycemia in intensive care patients with a least one organ dysfunction. the hyperglycemia is defined fasting glucose\> 1.26 g / l twice or need for treatment with insulin)

Secondary

Measure	Time frame	Description
Changes in inflammatory markers	one year after inclusion	—
Changes in serum lipid profile	one year after inclusion	Changes in cholesterol total, LDL cholesterol, HDL cholesterol and triglycerides
Changes in liver enzymes	one year after inclusion	Changes in total alanine transaminase (ALT) total gamma-GT total aspartate transaminase (AST)
Insulin Resistance (HOMA)	one year after inclusion	Calculated using the updated homeostasis model assessment (HOMA) calculator.Higher numbers indicate higher insulin resistance. There are no established cutoffs indicating impaired resistance.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORMercedes Jourdain, MD, PhD

University Hospital, Lille

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 15, 2026